Skip to main content
Erschienen in: Journal of Cancer Education 4/2021

01.08.2021

Dominican Provider Practices for Cervical Cancer Screening in Santo Domingo and Monte Plata Provinces

verfasst von: Erica Liebermann, Marilyn J. Hammer, Natalia Frías Gúzman, Nancy Van Devanter, Danielle Ompad

Erschienen in: Journal of Cancer Education | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Cervical cancer is the second leading cause of cancer death for women in the Dominican Republic. Pap smear screening in the Dominican Republic has not achieved adequate reduction in cervical cancer mortality. The purpose of this study was to examine Dominican provider practices for cervical cancer screening and the use of national or international screening guidelines. We surveyed 101 gynecology specialists, 50 non-specialists, and 51 obstetrics-gynecology residents in the Santo Domingo and Monte Plata provinces of the Dominican Republic regarding their cervical cancer screening practices and use of guidelines. Bivariate (chi-square) analyses were conducted to compare screening practices by demographic and practice characteristics. The majority of providers followed WHO guidelines (62.9%) and/or Dominican national norms (59.4%). The majority (87%) of providers use time since first sexual activity as the basis for screening initiation; 96% advise screening every 6–12 months. The most commonly used screening test is the conventional Pap smear. Colposcopy was recommended most often for all abnormal Pap results. Dominican providers report they follow national and/or international cervical cancer screening guidelines. They do not follow age-based screening guidelines, nor have they adopted an extended interval for screening and continue to recommend screening at least annually. A culture of early and frequent screening has consequences in terms of cost, high demand for follow-up services, and reduced capacity to reach the populations at highest risk. Early screening also may challenge the acceptability of adopting alternative screening technologies such as HPV testing.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
5.
Zurück zum Zitat Saslow D et al (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3):147–172CrossRef Saslow D et al (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3):147–172CrossRef
7.
Zurück zum Zitat Jeronimo J et al (2016) Secondary prevention of cervical cancer: ASCO Resource-Stratified Clinical Practice Guideline. J Glob Oncol:JGO006577 Jeronimo J et al (2016) Secondary prevention of cervical cancer: ASCO Resource-Stratified Clinical Practice Guideline. J Glob Oncol:JGO006577
8.
Zurück zum Zitat Liebermann EJ et al (2019) Barriers to Cervical cancer screening and treatment in the Dominican Republic: perspectives of focus group participants in the Santo Domingo Area. J Transcult Nurs:104365961984624 Liebermann EJ et al (2019) Barriers to Cervical cancer screening and treatment in the Dominican Republic: perspectives of focus group participants in the Santo Domingo Area. J Transcult Nurs:104365961984624
10.
Zurück zum Zitat Stormo AR et al (2012) Bolivian health providers’ attitudes toward alternative technologies for cervical cancer prevention: a focus on visual inspection with acetic acid and cryotherapy. J Womens Health 2002 21(8):801–808 Stormo AR et al (2012) Bolivian health providers’ attitudes toward alternative technologies for cervical cancer prevention: a focus on visual inspection with acetic acid and cryotherapy. J Womens Health 2002 21(8):801–808
11.
Zurück zum Zitat Townsend J, Stormo A, Roland K, Buenconsejo-Lum L, White S, Saraiya M (2014) Current cervical cancer screening knowledge, awareness, and practices among US affiliated Pacific Island providers: opportunities and challenges. ONCOLOGIST 19(4):383–393CrossRef Townsend J, Stormo A, Roland K, Buenconsejo-Lum L, White S, Saraiya M (2014) Current cervical cancer screening knowledge, awareness, and practices among US affiliated Pacific Island providers: opportunities and challenges. ONCOLOGIST 19(4):383–393CrossRef
12.
Zurück zum Zitat Hilton A, Skrutkowski M (2002) Translating instruments into other languages: development and testing processes. Cancer Nurs 25(1):1–7CrossRef Hilton A, Skrutkowski M (2002) Translating instruments into other languages: development and testing processes. Cancer Nurs 25(1):1–7CrossRef
13.
Zurück zum Zitat Maneesriwongul W, Dixon JK (2004) Instrument translation process: a methods review. J Adv Nurs 48(2):175–186CrossRef Maneesriwongul W, Dixon JK (2004) Instrument translation process: a methods review. J Adv Nurs 48(2):175–186CrossRef
14.
Zurück zum Zitat Nayar R, Wilbur D (eds) (2015) The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes, 3rd edn. Springer International Publishing Nayar R, Wilbur D (eds) (2015) The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes, 3rd edn. Springer International Publishing
15.
Zurück zum Zitat Stormo AR, de Moura L, Saraiya M (2014) Cervical cancer-related knowledge, attitudes, and practices of health professionals working in Brazil’s network of primary care units. Oncologist 19(4):375–382CrossRef Stormo AR, de Moura L, Saraiya M (2014) Cervical cancer-related knowledge, attitudes, and practices of health professionals working in Brazil’s network of primary care units. Oncologist 19(4):375–382CrossRef
16.
Zurück zum Zitat Ogilvie G, Nakisige C, Huh WK, Mehrotra R, Franco EL, Jeronimo J (2017) Optimizing secondary prevention of cervical cancer: recent advances and future challenges. Int J Gynecol Obstet 138:15–19CrossRef Ogilvie G, Nakisige C, Huh WK, Mehrotra R, Franco EL, Jeronimo J (2017) Optimizing secondary prevention of cervical cancer: recent advances and future challenges. Int J Gynecol Obstet 138:15–19CrossRef
Metadaten
Titel
Dominican Provider Practices for Cervical Cancer Screening in Santo Domingo and Monte Plata Provinces
verfasst von
Erica Liebermann
Marilyn J. Hammer
Natalia Frías Gúzman
Nancy Van Devanter
Danielle Ompad
Publikationsdatum
01.08.2021
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 4/2021
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-020-01690-9

Weitere Artikel der Ausgabe 4/2021

Journal of Cancer Education 4/2021 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.